Epithelial Ovarian Cancer, Metabolomics, Transcriptomics, Tumorigenesis, Tumor Invasiveness, Whole Exome Sequencing
Conditions
Brief summary
This study aims to analyze the multi-omics results between epithelial ovarian cancer (EOC) patient with different FIGO stages and pathological subtypes. The multi-omics profiles include whole exome sequencing, analysis of transcriptomics and metabolomics. A comprehensive multi-omics will reveal the invasiveness and tumorigenesis of EOC.
Interventions
COMBINATION_PRODUCTA multi-omics analysis
A multi-omics analysis including whole exome sequencing, transcriptomics and metabolomics.
Sponsors
Lei Li
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
No
Inclusion criteria
* Confirmed primary epithelial ovarian cancer * Signed an approved informed consents * Feasible for biopsy
Exclusion criteria
* Not meeting all of the inclusion criteria
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequencies of somatic driving mutations | Two years | The differences of frequencies of somatic driving mutations will be compared between patients of different FIGO stages and different pathological subtypes. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Frequencies of alteration of RNA expression | Two years | The alteration of RNA expression, including mRNA, miRNA, and lncRNA, will be compared between patients of different FIGO stages and different pathological subtypes. |
| Frequencies of alteration of protein expression and signal pathway | Two years | The alteration of patterns of protein expression and signal pathway will be compared between patients of different FIGO stages and different pathological subtypes. |
| Progression-free survival | Five years | Progression-free survival between patients with differential expressed multi-omics will be compared. |
Countries
China
Contacts
Primary ContactLei Li, M.D.
Outcome results
None listed